Abstract. Programmed cell death 4 (PDCD4) was recently identified as a novel tumor suppressor gene. The loss of PDCD4 expression was found in several types of human cancer cell lines. To date, however, the status of PDCD4 expression in human glioma tissue is not known. In the present study, the expression of PDCD4 in 30 glioma samples was determined at both mRNA and protein levels by means of RT-PCR, Western blotting, and immunohistochemistry. Herein, we demonstrate, for the first time, that 47% (14/30) of glioma samples lost the expression of PDCD4 mRNA, and 77% (23/30) of glioma samples lacked the PDCD4 protein expression, whereas adjacent normal glial tissues expressed high levels of PDCD4 mRNA and protein. Furthermore, the loss of PDCD4 expression does not significantly correlate with the pathological and clinical features of the glioma. Our new data suggest that the loss of PDCD4 expression is a frequent event in human glioma and may partially contribute to the development of the tumor.
Introduction
Human gliomas are the most common tumor that arises in the central nervous system. As nearly half of gliomas are histologically malignant, therapy of gliomas is one of the most formidable challenges in human malignancies. Over the past two decades, the overall survival of patients suffering from the disease has been improved little, despite therapeutic strategies to employ surgery in combination with radiation and chemotherapy (1, 2) . Therefore, studies of the molecular biology of the tumor are key issues to getting insight into the mechanisms underlying the pathogenesis of glioma and, in turn, leading to effective therapeutics finally. In recent years, there has been considerable progress in understanding the genetic alterations that cause the initiation and progression of gliomas (3) . It is now known that malignant gliomas arise from a number of well-characterized genetic alterations and activations of oncogenes and inactivation of tumor suppressor genes (1) . Programmed cell death 4, PDCD4, was recently identified as a novel tumor suppressor gene. To date, however, its role in human glioma is not clear.
PDCD4 was first cloned as a gene whose elevated expression is associated with the occurrences of apoptosis in mouse cell lines (4) . Subsequently, certain other different mammalian homologues of PDCD4 were identified. So, PDCD4 represents a new pre-apoptotic gene. It is generally accepted that cancer is a disease with deregulated cell proliferation, abnormal differentiation and disturbed apoptosis (5) . Thus, it is conceivably inferred that PDCD4 may exert a crucial role in the mechanisms underlying carcinogenesis. Indeed, the following studies demonstrated that PDCD4 was able to inhibit tumor promoter-induced transformation in the mouse JB6 model system (6) (7) (8) , thereby confirming that PDCD4 acts as a novel tumor suppressor gene. Furthermore, previous studies have shown that PDCD4 exerted its antitumor roles via regulating signal transduction pathways (9, 10) .
Human PDCD4 is first cloned from a human glioma library, which is highly homologous to the mouse PDCD4 (11, 12) . It is expressed ubiquitously in human normal tissues, whereas loss of its expression is found in several types of human cancer cell lines (13) , and in primary lung cancer (14) and in primary pancreatic cancer (15) . However, the status of PDCD4 expression in human primary gliomas is unknown. In the present study, the expression of PDCD4 in 30 primary gliomas was determined at both mRNA and protein levels by means of RT-PCR, Western blotting and immunohistochemistry. RT-PCR. Total RNAs were extracted from 30 glioma specimens, 3 normal tissue specimens and glioma cell line (U251) cells using a modified TRIzol ® one-step extraction method (16, 17) . CDNA was reversely transcribed by the Reverse-Transcribe kit according to the manufacturer's instructions. The reaction was first performed at 70˚C for 10 min, and then at 42˚C for 1 h, followed by 95-99˚C for 5 min to stop the reaction. PCR was performed using PDCD4 specific primers (sense 5'-CCA, AAG, AAA, GGT, GGT, GCA-3', and antisense 5'-TGA, GGT, ACT, TCC, AGT, TCC-3'). The PCR reaction mix for each sample included 12.5 μl of 2X Master mix (0.1 U TaqDNA polymerase, 500 μM dNTP, 3 mM MgCl 2 , 100 mM KCl, 20 mM TrisHCl), 0.5 μl of forward primer (5 μM), 0.5 μl of reverse primer (5 μM), 1 μl of the DNA sample, and 10.5 μl of H 2 O. The sample was denatured at 94˚C for 2 min, followed by 35 cycles of 95˚C for 1 min 30 sec, 66˚C for 1 min 30 sec, and 72˚C for 1 min 30 sec with an extension cycle at 72˚C for 5 min. For each PCR reaction, pure water (no DNA template) was used as a reagent negative control. Human ß-actin was amplified as an internal control from parallel samples. All PCR products were electrophoresed on a 1.5% agarose gel. The RT-PCR was performed at least twice in independent experiments.
Materials and methods

Carcinoma
SDS-PAGE and Western blotting.
The proteins were extracted from tissue samples using a modified TRIzol ® one-step extraction method (16, 17) . In brief, tissues were homogenized and then lysed by TRIzol. After centrifution, upper phase containing RNA was removed for RNA extraction, and then interphase and organic phase were collected for protein extraction. The proteins were precipitated by acetone. After washing three times, the protein extraction was dissolved in loading buffer (1 mM Tris·Cl, 3% SDS, 60% glycerol, 75 mM DTT). Of each sample 25 μg was analysed by SDS-PAGE on a 12% gel and then was transferred to the nitrocellulose membrane. After blocking with 5% skim milk in TBST containing 0.1% Tween-20 (Sigma-Aldrich), the membrane was incubated with rabbit anti-human PDCD4 antibody (1:10000) or human ß-actin antibody (1:1000) at 4˚C overnight, washed three times, and incubated with peroxidase-conjugated goat anti-rabbit IgG. Following washing, immunoreactive bands were visualized using the enhanced chemiluminescence method according to the manufacturer's instructions (ECL, Amersham Biosciences, UK). Equal concentrations of each protein were determined by Bradford analysis and Western blotting was performed at least twice in independent experiments.
Immunohistochemistry. A 4-to 6-μm section was prepared from freezed glioma tissues and normal brain tissues adjacent to tumor at -80˚C using the freezing microtome and used for H&E staining or immunostaining. After being fixed by cold acetone, the slides were washed 3 times with PBS, blocked for endogenous peroxidase activity, preincubated with goat serum, and then incubated with anti-PDCD4 antibody (1:200) for 1 h at room temperature in a humid chamber. The sections were washed three times for 3 min at room temperature with PBS and then visualized with Rabbit IgG avidin-biotin peroxidase complex kit and DAB peroxidase substrate kit (Maixin Co., Fuzhou, P.R. China). The nuclei were counterstained with hematoxylin. Negative controls for the specificity of immunohistochemical reactions were performed by replacing the primary antibody with PBS. All of the slides were independently analyzed by two pathologists. Statistical analysis. The ¯2 test was used to analyse the correlation of expression of PDCD4 protein with pathological characters. p-values <0.05 were considered statistically significant. All calculations were performed through the SPSS statistical software package.
Results
Lacking or decreased expression of PDCD4 mRNA in gliomas.
To study the role of PDCD4 in the gliomas, we firstly examined the PDCD4 expression at RNA level by semiquantitative RT-PCR according to the OD value of PDCD4 mRNA expression normalized to ß-actin: -, no detection; +, 0.01 to 0.49; ++, 0.5 to 0.99; +++, 1.0 to 1.99; ++++, ≥2.00. As illustrated in Fig. 1 , all of three normal brain tissues adjacent to the tumor lesion expressed a high level of PDCD4 mRNA, whereas most of the gliomas expressed reduced or lacked PDCD4 mRNA. In 30 glioma specimens, 14 (47%) lost PDCD4 mRNA expression (Table I ). In the remaining 16 glioma samples, 12 (40% of 30) appeared differently reduced in PDCD4 mRNA expression compared with three normal tissue controls. For example, PDCD4s were lost in the glioma samples 2, 3, and 7 and distinctly reduced in the glioma samples 4, 5, and 6; while glioma sample 1 was almost identical with the normal tissue control as shown in Fig. 1 . U251 is a cell line originated from glioma. It has been reported ONCOLOGY REPORTS 17: 123-128, 2007 Table I. Analysis of PDCD4 expression in gliomas. Anaplastic oligodendroglioma  26  ---GII-III  Astrocytic tumours  27  ---GII-III  Oligodendroglioma  28  ---GIV  Glioblastoma  29  ---GII-III  Astrocytic tumours  30  ---GIV  Glioblastoma  31 ---
-----------------------------------------------------------------------------------------------------
No. RNA Protein Grade Classification ----------------- WB IH -
----------------------------------------------------------------------------------------------------
GII-III Astrocytic tumours -----------------------------------------------------------------------------------------------------
The pathological analysis was according to World Health Organization (WHO) criteria (1999). The level of PDCD4 mRNA levels were analysed by semi-quantitative RT-PCR according to the OD value of PDCD4 mRNA expression normalized to ß-actin: -, no detection; +, 0.01 to 0.49; ++, 0.5 to 0.99; +++, 1.0 to 1.99; ++++, ≥2.00. Expression of PDCD4 protein was detected by Western blotting (WB) and immunohistochemistry (IH): +, expression; -, loss.
-----------------------------------------------------------------------------------------------------
that the cell line almost loses expression of PDCD4 mRNA (14) . Our result was identical with that of the previous report.
High frequent loss of PDCD4 protein expression in gliomas.
Based on the above studies, we further examined the expression of PDCD4 protein by Western blotting and immunohistochemistry. The data from Western blot experiment showed that the loss of PDCD4 proteins was more than that of PDCD4 mRNA (Table I ). In 30 cases of the gliomas, 23 (77%) exhibited no relevant PDCD4 bands and the other 6 showed weak PDCD4 bands, compared with normal brain tissues adjacent to tumor, which showed strong PDCD4 expression (Fig. 2) . Only samples 1, 4, and 6 had slight expression. While other samples, e.g. samples 2, 3, 5, and 7, were lost in the protein level. Noteworthily, some gliomas such as sample 5 expressed PDCD4 mRNA but not PDCD4 protein. These suggested that loss of PDCD4 expression in certain gliomas might occur after mRNA transcription.
Immunohistochemistry analysis showed that the PDCD4 protein expression in the tumor tissue sections were similar to those from Western blot analysis (Table I ). The tumor adjacent tissue such as case 24 showed very strong PDCD4 expression (Fig. 3A) , while its paired tumor tissue exhibited decreased PDCD4 staining (Fig. 3B) . In certain gliomas, such as case 29, there was almost no relevant PDCD4 staining (Fig. 3C ). In addition, Fig. 3 showed that the positive PDCD4 staining localized in cytoplasm.
The loss of PDCD4 in gliomas had no significant relationships with tumor grade or histological type. To explore the significance of no PDCD4 protein in gliomas, we further analysed the relationship between loss of PDCD4 protein and clinicopathological parameters. As expected, there was no significant correlation of lack of PDCD4 expression with sex, age, and tumor size (data not shown). Unexpectedly there was also no significant relationship between loss of PDCD4 expression and tumor grade or histological type (Fig. 4) .
Discussion
Previous study of mammalian cell lines has confirmed that PDCD4 acts as a novel tumor suppressor gene (12, (18) (19) (20) (21) (22) (23) (24) . Up to now, however, the genetic variability of PDCD4 in human primary tumor tissues was only limited in lung cancer and pancreatic cancer (15) . The result analyzed by Chen et al demonstrated that 83% of lung cancers lacked the expression of PDCD4 proteins and found that loss of PDCD4 expression in human lung cancer samples correlated with tumor progression and prognosis (14) . In the present study, we clearly demonstrate, for the first time, that high frequent loss of PDCD4 expression exists in primary gliomas, of which 47% (14/30) lost the expression of PDCD4 mRNA, and 77% (23/30) lacked the PDCD4 protein expression. However, the loss of PDCD4 expression in gliomas had no significant relationship with tumor grade, histological type or prognosis.
At present, the molecular basis for the PDCD4 expression pattern is unclear. In this study, certain samples lost PDCD4 expression in the mRNA level, whereas other samples lost it in the protein level. The explanation for the loss of expression might be tissue-specific or related to mutation of the initiator or to certain genes that control PDCD4 expression (25, 26) . In fact, the inactivation of the tumor suppressor gene may not only happen in the transcription level through gene mutation but also in the protein level for the change of certain modulate genes as a result of reduced gene expression. Our results show that PDCD4 expression is higher in the normal tissue, i.e. tumor adjacent tissue, than the tumor tissue for the paired tumor sample by immunohistochemistry. We presume that the alteration may be related with the initiation of the tumor by inactivation of the suppressor gene. In addition, our results indicate that loss or absence of PDCD4 expression may play a crucial role in the pathogenesis of glioma, maybe via downregulation of apoptosis.
Our data showed that loss of PDCD4 expression had no significant association with tumor grade or histological type. So the significance of high frequent loss of PDCD4 expression in gliomas is unclear. Interestingly, Jansen et al found that the PDCD4 expression was associated with drug sensitivity (13) . It has been observed that most gliomas are not sensitive to drugs. Maybe the high frequent loss of PDCD4 expression in gliomas relates to the low drug sensitivity of the tumor.
Therapeutic strategies to up-regulate PDCD4 expression in gliomas may offer a promising treatment for the patients. However, this needs to be confirmed in the future.
In conclusion, our new results suggest that loss or absence of PDCD4 expression may be a key factor in the tumorigenesis of glioma. However, the precise mechanism by which PDCD4 expression affects the tumorigenesis of glioma needs to be investigated further in a large set of patient samples. 
